Johnson & Johnson Terminate Agreements with Orexo

Sweden’s Orexo suffered a major setback yesterday after the announcement that Johnson & Johnson had decided to end the firms’ anti-inflammatory collaboration. The agreement with the healthcare company’s Janssen Pharmaceuticals unit aligned around two research projects in the arachidonic acid field. The OX-CLI and OX‑ESI programmes were concentrated on developing treatments for asthma, chronic obstructive

Continue Reading

Johnson & Johnson and Vertex’s Incivo Receives EU Approval

he European Commission has approved Johnson & Johnson and Vertex Pharmaceuticals’ hepatitis C drug, Incivo (telaprevir), a direct-acting antiviral protease inhibitor, for the treatment of genotype-1 chronic hepatitis C virus, in combination with peginterferon alfa and ribavirin. The approval was based on data from three Phase III studies involving 2,290 patients. Two of these studies,

Continue Reading